Individual response
|
|
233
|
25341
|
March 18, 2023
|
Randomization in a diagnostic study - necessary?
|
|
3
|
123
|
March 16, 2023
|
Appropriate model for combined data from two RCTs
|
|
10
|
160
|
March 8, 2023
|
RCT with missing follow-up outcomes: ANCOVA + MI vs Mixed-Effects Modelling?
|
|
50
|
2158
|
March 7, 2023
|
FDA "Bad Habits"
|
|
7
|
769
|
March 4, 2023
|
Resources for handling blocked randomization in the analysis of RCTs
|
|
10
|
243
|
February 11, 2023
|
Toward Guidelines for RCT Measurements.. What are the characteristics of an acceptable measurement for RCT?
|
|
0
|
365
|
February 10, 2023
|
What is a fake measurement tool and how are they used in RCT
|
|
46
|
13686
|
January 23, 2023
|
Language for communicating frequentist results about treatment effects
|
|
197
|
98277
|
January 18, 2023
|
Rescue analysis for % change from baseline as an outcome in RCT
|
|
16
|
613
|
January 16, 2023
|
The Clinical and Statistical Saga of Thrombolysis in Acute Ischemic Stroke
|
|
11
|
1075
|
December 21, 2022
|
Information, Evidence, and Statistics for critical research appraisal
|
|
17
|
938
|
November 21, 2022
|
Is it appropriate to present confidence intervals (CIs) for the outcome in each treatment group in the context of clinical trials?
|
|
5
|
442
|
November 2, 2022
|
Background to PFS endpoint
|
|
19
|
5378
|
October 6, 2022
|
Quality of remdesivir trials
|
|
54
|
15383
|
October 5, 2022
|
Run-in phase in RCTs
|
|
10
|
7803
|
September 24, 2022
|
Cdisc in academia
|
|
1
|
524
|
September 7, 2022
|
Patient-specific treatment effects in RCTs: why should one present them?
|
|
1
|
1565
|
August 13, 2022
|
Analyzing compositional outcome data
|
|
5
|
2882
|
July 28, 2022
|
Which to make as the primary analysis
|
|
1
|
1499
|
July 25, 2022
|
Non-inferiority and choice of scale (absolute vs relative)
|
|
4
|
1105
|
July 23, 2022
|
Evidence Based Decision Making and Meta-Analysis -- An Information Theoretic Critique
|
|
1
|
1819
|
June 10, 2022
|
Logistics of treatment effect estimation with interim analyses
|
|
1
|
885
|
June 1, 2022
|
Should adverse effects be adjusted for multiple comparisons?
|
|
4
|
2166
|
May 24, 2022
|
Summary Statistics vs Raw Data
|
|
8
|
7386
|
May 7, 2022
|
Methodology: Benefit Risk Assessment when Risk and Benefit are only observed in different timing
|
|
5
|
1106
|
April 18, 2022
|
Covariate adjustment in non-inferiority trials
|
|
3
|
2130
|
April 14, 2022
|
RCT and "Mathematical Embellishment"
|
|
2
|
2541
|
April 5, 2022
|
Chi-Squared for relative risk
|
|
1
|
1673
|
March 27, 2022
|
Analysis of 2x2 trial with anticipated treatment interaction
|
|
9
|
2654
|
March 25, 2022
|